English

Interim report January–March 2022: Building on our strong growth momentum

Report this content

First quarter

  • Sales of SEK 752 (379) million, corresponding to an increase of 98% in SEK whereof currency effect 13%, acquired growth 74% and organic growth 11%.
  • Consumables increased sales by 26% in SEK, Technologies by 4% in SEK, and Genetic Services contributed with sales of SEK 304 million.
  • Strong growth in all market regions: Americas 255%, EMEA 85%, Japan Pacific 21% and Asia 19% in local currencies.
  • Operating income before depreciation and amortisation (EBITDA) was SEK 228 (163) million, corresponding to a margin of 30.4% (43.0). EBITDA per share increased 13%.
  • Net income was SEK 82 (119) million, resulting in earnings per share of SEK 0.60 (1.09).

    Pro forma
  • Sales, adjusted for discontinuing Covid business, increased by 18% in SEK, and 11% in local currencies.
  • EBITDA margin of 30.4% (34.4%).

Gothenburg, April 22, 2022
VITROLIFE AB (publ)
Thomas Axelsson, CEO

Queries should be addressed to:
Thomas Axelsson, CEO, Tel: +46 31 721 80 01
Patrik Tolf, CFO, Tel: +46 31 766 90 21

This information is information that Vitrolife AB is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out above, at 8.00 am CET on April 22, 2022.

_____________________________________________________________________________________________________________________________________________________________

Vitrolife is a global provider of medical devices and genetic services. Based on science and advanced research capabilities, we develop services and products for personalized genetic information and medical device products. Vitrolife is supporting our customers by improving their clinical practice and the outcome of the patient’s fertility treatment. Currently, we are approximately 1,200 people worldwide, headquartered in Gothenburg, Sweden.

Vitrolife’s products and services are available in more than 110 countries, through our own presence in 30 countries and a network of distributors. Vitrolife is a sustainable market leader and aims to be the preferred partner to the IVF-clinics by providing superior products and services with the vision to fulfil the dream of having a baby. The Vitrolife share is listed on the Nasdaq Stockholm.
_____________________________________________________________________________________________________________________________________________________________

Vitrolife AB (publ), Box 9080, SE-400 92 Gothenburg, Sweden. Corporate identity number 556354-3452.Tel: +46 31 721 80 00. Fax: +46 31 721 80 99.
E-mail: info@vitrolife.com. Website: www.vitrolife.com.

Subscribe

Documents & Links